Marinus Pharmaceuticals, Inc. (MRNS)

Market Cap	12.69M
Revenue (ttm)	31.47M
Net Income (ttm)	-140.49M
Shares Out	55.19M
EPS (ttm)	-2.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,134,752
Open	0.241
Previous Close	0.239
Day's Range	0.230 - 0.247
52-Week Range	0.230 - 11.260
Beta	1.19
Analysts	Buy
Price Target	4.28 (+1,760.87%)
Earnings Date	Nov 12, 2024

About MRNS

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABA...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 31, 2014
• Employees: 166
• Stock Exchange: NASDAQ
• Ticker Symbol: MRNS
• Website: https://marinuspharma.com

Financial Performance

In 2023, Marinus Pharmaceuticals's revenue was $30.99 million, an increase of 21.63% compared to the previous year's $25.48 million. Losses were -$141.41 million, 613.6% more than in 2022.

Analyst Forecast

According to 12 analysts, the average rating for MRNS stock is "Buy." The 12-month stock price forecast is $4.28, which is an increase of 1,760.87% from the latest price.

Price Target

$4.28

(1,760.87% upside)

Analyst Consensus: Buy